The Effects of Compression Therapy at Different Pressure Levels on Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Patients: A Randomized Controlled Trial
Clinical Breast Cancer · 2026
DOI: 10.1016/j.clbc.2025.08.009 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Breast Cancer, 2026. Verfasst von Hong Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: North China University of Science and Technology, Tangshan 063210,China. Hauptthemen laut MEDLINE: Breast Neoplasms, Peripheral Nervous System Diseases, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 29 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE: This study aims to examine the effects of compression therapy at different pressure levels on chemotherapy-induced peripheral neuropathy (CIPN). METHODS: A total of 108 breast cancer patients who developed CIPN after their first albumin-bound paclitaxel chemotherapy were randomly divided into 3 groups(1:1:1): control group, experimental group 1 (Grade II pressure: 23-32 mmHg), and experimental group 2 (Grade III pressure: 34-46 mmHg). The control group was given standard care, while the experimental groups underwent compression therapy in addition to standard care. CIPN incidence, symptom severity, and its impact on activities of daily living (ADL) were assessed at baseline, after the completion of the third and fifth chemotherapy cycles. RESULTS: After completing 3 chemotherapy cycles, CIPN incidence did not differ significantly among the groups (P > .05). After 5 cycles, the incidence of CIPN (≥ Grade 1) was significantly lower in both experimental groups compared to the control group (P < .05), with Experimental Group 2 also showing lower CIPN incidence (≥ Grade 2) than the control and Experimental Group 1 (P < .05). Both Grade II and III compression therapies alleviated CIPN symptoms and improved ADL, but Experimental Group 2 demonstrated superior efficacy after 5 cycles (P < .05). Significant differences in symptom severity and ADL impact were observed across group, time, and interaction effects (P < .001). CONCLUSION: Compression therapy reduces CIPN incidence, alleviates symptoms, and improves ADL. Over longer intervention periods, Grade III pressure yields superior outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- North China University of Science and Technology, Tangshan 063210,China.
- Tangshan People's Hospital, Tangshan 063000,China.
- Tangshan People's Hospital, Tangshan 063000,China. Electronic address: zhoulizhi72@126.com.
Zitieren
APA
Li, H., Fan, Y., Xu, H., Qu, H., Wang, Y., Yu, D., & Zhou, L. (2026). The Effects of Compression Therapy at Different Pressure Levels on Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Patients: A Randomized Controlled Trial. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2025.08.009
Vancouver
Li H, Fan Y, Xu H, Qu H, Wang Y, Yu D, et al. The Effects of Compression Therapy at Different Pressure Levels on Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Patients: A Randomized Controlled Trial. Clinical Breast Cancer. 2026. doi:10.1016/j.clbc.2025.08.009
BibTeX
@article{Li2026,
author = {Li, Hong and Fan, Yijing and Xu, Huiqian and Qu, Haihong and Wang, Yang and Yu, Dandan and Zhou, Lizhi},
title = {The Effects of Compression Therapy at Different Pressure Levels on Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Patients: A Randomized Controlled Trial},
journal = {Clinical Breast Cancer},
year = {2026},
doi = {10.1016/j.clbc.2025.08.009}
}
EUVIMED